JUL 11, 2018 2:56 AM PDT

Blood Pressure Medication 'Verapamil' Stimulates Insulin Production

WRITTEN BY: Nouran Amin

A common blood pressure medication, verapamil, may improve outcomes for patients with Type 1 diabetes.

According to researchers at the University of Alabama (UAB) at Birmingham Comprehensive Diabetes Center, diabetes affects more than 30 million Americans. Now, research at UAB has led to the discovery of a "safe and effective novel therapy to reduce insulin requirements and hypoglycemic episodes in adult subjects with recent onset Type 1 diabetes."

Furthermore, verapamil, which is administered orally, will allow the patient's body to produce their very own insulin which limits the number of insulin injections needed.

"While this research is not an end-all cure for Type 1 diabetes, these findings are getting us closer to disease-altering therapies that can enable individuals with Type 1 diabetes to have more control over their disease and maintain some of their body's own insulin production," said Anath Shalev, director of UAB's CDC.

Published in Nature Medicine, the research team at UAB found a way to promote the patient's own beta cell function and insulin production.

When Shalev discovered that verapamil reversed the effects of Type 1 diabetes, human trials began.

Over a year, the clinical trials studied 24 patients between the ages of 18-45. 11 of these patients received the blood pressure medication and the other 13 received a placebo.

"Although this is a smaller sample group, our trial results give us promise that subjects with Type 1 diabetes have therapy options and that we are nearing a more effective way to deal with this disease," said Fernando Ovalle, director of UAB's Comprehensive Diabetes Clinic and co-principal investigator of the study. "Beyond verapamil allowing subjects with Type 1 diabetes the ability to live a life with less external insulin dependence, these findings will impact the quality of life that they can have."

By improving blood sugar control, patients suffering from Type 1 diabetes will experience fewer heart attacks, blindness, kidney disease and other issues.

 

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
MAY 12, 2020
Immunology
MAY 12, 2020
Disabling Genes in Immune Cells Prevents Obesity
Obesity is a $1.7 trillion problem in the United States — a value almost 10% of the nation’s gross domestic ...
JUN 08, 2020
Cancer
JUN 08, 2020
Using Soft Tissue Sarcoma's Immune Defense as a Biomarker
Programmed cell death protein 1 (PD-1) has been a big player in the treatment of both autoimmune disease and cancer. PD- ...
JUN 13, 2020
Neuroscience
JUN 13, 2020
High Doses of Ketamine Can Switch Off the Brain
Researchers from the University of Cambridge, England, have found that high doses of ketamine temporarily switch off the ...
JUN 05, 2020
Drug Discovery & Development
JUN 05, 2020
Biofriendly Drug Design for Neurological Diseases
Carbon quantum dots are a class of nanoparticles that can be placed to good use for treating neurodegenerative diseases ...
JUN 10, 2020
Drug Discovery & Development
JUN 10, 2020
Does Your Gut Microbiota Alter Drug Activity?
Scientists have created a systematic way to evaluate how the microbial community in our gut influences drug behavior. Fi ...
JUN 23, 2020
Drug Discovery & Development
JUN 23, 2020
Psychedelic DMT to Enter Clinical Trials
Neuro-pharmaceutical company, MindMed, has announced that it will begin a double-blind placebo-controlled Phase 1 clinic ...
Loading Comments...